Table 1 Characteristics of patients in the post-matching cohort

PSM score

0.33 ± 0.20

0.33 ± 0.20

-0.009

0.993

Age (years)

0.030

0.863

≤ 60

156 (56.90%)

154 (56.20%)

>60

118 (43.10%)

120 (43.80%)

BMI

22.90 (21.30-24.49)

22.66 (20.83–24.24)

-1.268

0.205

Tumor size (cm)

2.969

0.227

≤ 2.70

36 (13.10%)

32 (11.70%)

2.70–4.40

110 (40.10%)

130 (47.40%)

>4.40

128 (46.70%)

112 (40.90%)

Obstruction before surgery

0.117

0.733

Absent

229 (83.60%)

226 (82.50%)

present

45 (16.40%)

48 (17.50%)

Sex

0.070

0.792

Male

172 (62.80%)

169 (61.70%)

Female

102 (37.20%)

105 (38.30%)

Family history of cancer

0.171

0.679

No

31 (11.30%)

28 (10.20%)

Yes

243 (88.70%)

246 (89.80%)

Post radiotherapy

1.129

0.288

No

260 (94.90%)

254 (92.70%)

Yes

14 (5.10%)

20 (7.30%)

Adjuvant chemotherapy

1.072

0.301

No

124 (45.30%)

112 (40.90%)

Yes

150 (54.70%)

162 (59.10%)

Vascular cancer embolus

1.185

0.276

Absent

189 (69.00%)

177 (64.60%)

Present

85 (31.00%)

97 (35.40%)

Histological grade

-0.801

0.423

Poorly

56 (20.40%)

41 (15.00%)

Moderately

187 (68.20%)

208 (75.90%)

Well

31 (11.30%)

25 (9.10%)

Stage

-0.222

0.825

I

5 (1.80%)

7 (2.60%)

II

83 (30.30%)

76 (27.70%)

III

138 (50.40%)

152 (55.50%)

IV

48 (17.50%)

39 (14.20%)

T stage

-1.096

0.273

T1

1 (0.40%)

5 (1.80%)

T2

13 (4.70%)

12 (4.40%)

T3

167 (60.90%)

175 (63.90%)

T4

93 (33.90%)

82 (29.90%)

N stage

-0.417

0.677

N0

105 (38.30%)

102 (37.20%)

N1

87 (31.80%)

102 (37.20%)

N2

82 (29.90%)

70 (25.50%)

M stage

-1.337

0.181

M0

229 (83.60%)

240 (87.60%)

M1

45 (16.40%)

34 (12.40%)

Primary tumor location

0.385

0.825

Right colon

63 (23.00%)

65 (23.70%)

Left colon

67 (24.50%)

72 (26.30%)

Rectum

144 (52.60%)

137 (50.00%)

ASA

6.472

0.087

1

1 (0.40%)

7 (2.60%)

2

198 (72.30%)

190 (69.30%)

3

59 (21.50%)

53 (19.30%)

4

16 (5.80%)

24 (8.80%)

Previous history of abdominal surgery

0.415

0.519

No

217 (79.20%)

223 (81.40%)

Yes

57 (20.80%)

51 (18.60%)

Neoadjuvant chemotherapy

2.409

0.121

No

264 (96.40%)

256 (93.40%)

Yes

10 (3.60%)

18 (6.60%)

preoperative comorbidities

Total patients

3.067

0.080

No

188 (68.60%)

202 (73.70%)

Yes

86 (31.40%)

72 (26.30%)

Cardiovascular disease

3.233

0.072

No

199 (72.60%)

217 (79.20%)

Yes

75 (27.40%)

57 (20.80%)

Cerebrovascular disease

2.639

0.104

No

264 (96.40%)

270 (98.50%)

Yes

10 (3.60%)

4 (1.50%)

COPD

3.067

0.080

No

271 (98.90%)

265 (96.70%)

Yes

3 (1.10%)

9 (3.30%)

Diabetes

0.029

0.865

No

255 (93.10%)

256 (93.40%)

Yes

19 (6.90%)

18 (6.60%)

CEA (ng/mL)

0.359

0.549

< 5

149 (54.40%)

142 (51.80%)

≥ 5

125 (45.60%)

132 (48.20%)

CA199 (kU/L)

1.189

0.275

< 37

212 (77.40%)

201 (73.40%)

≥ 37

62 (22.60%)

73 (26.60%)

CA125 (U/mL)

0.069

0.793

< 35

240 (87.60%)

242 (88.30%)

≥ 35

34 (12.40%)

32 (11.70%)